{"id":"ceftazidime-avibactam-fosfomycin","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Phlebitis at infusion site"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ceftazidime is a third-generation cephalosporin that binds penicillin-binding proteins and inhibits cell wall synthesis. Avibactam is a beta-lactamase inhibitor that protects ceftazidime from enzymatic degradation by resistant organisms. Fosfomycin is a phosphonic acid antibiotic that inhibits MurA enzyme, blocking early-stage peptidoglycan synthesis. The combination provides enhanced activity against multidrug-resistant gram-negative bacteria including carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa.","oneSentence":"Ceftazidime-avibactam inhibits bacterial cell wall synthesis while avibactam protects against beta-lactamase degradation, and fosfomycin disrupts peptidoglycan cross-linking through a different pathway to provide synergistic broad-spectrum coverage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:29:53.069Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated urinary tract infections (cUTI)"},{"name":"Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)"},{"name":"Complicated intra-abdominal infections (cIAI)"},{"name":"Multidrug-resistant gram-negative bacterial infections"}]},"trialDetails":[{"nctId":"NCT06717594","phase":"","title":"PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2023-12-01","conditions":"Gram Negative Infections, Antimicrobial Resistance (AMR)","enrollment":60},{"nctId":"NCT07063095","phase":"PHASE3","title":"A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections","status":"RECRUITING","sponsor":"Angela HUTTNER","startDate":"2025-08-25","conditions":"Gram Negative Infections, Sepsis and Septic Shock","enrollment":100},{"nctId":"NCT07004049","phase":"PHASE4","title":"Optimising TREATment for Severe Gram-Negative Bacterial Infections","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-04-21","conditions":"Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia","enrollment":600},{"nctId":"NCT06419296","phase":"","title":"Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.","status":"COMPLETED","sponsor":"Hospital Italiano de Buenos Aires","startDate":"2024-06-01","conditions":"Bacteremia","enrollment":265},{"nctId":"NCT04882085","phase":"PHASE4","title":"Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-26","conditions":"Urinary Tract Infection, Acute Pyelonephritis, Hospital Acquired Pneumonia","enrollment":60},{"nctId":"NCT06651047","phase":"","title":"PK/PD Analysis of Ceftazidime/Avibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections","status":"RECRUITING","sponsor":"University of Bologna","startDate":"2024-07-09","conditions":"Gram Negative Infection, Antimicrobial Resistance (AMR)","enrollment":120},{"nctId":"NCT05048693","phase":"","title":"Use of New Antibiotics in Sweden","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2021-11-01","conditions":"Multi-antibiotic Resistance","enrollment":41},{"nctId":"NCT05850871","phase":"NA","title":"Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-01-06","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":427}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ceftazidime-avibactam + Fosfomycin","genericName":"Ceftazidime-avibactam + Fosfomycin","companyName":"National University of Singapore","companyId":"national-university-of-singapore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ceftazidime-avibactam inhibits bacterial cell wall synthesis while avibactam protects against beta-lactamase degradation, and fosfomycin disrupts peptidoglycan cross-linking through a different pathway to provide synergistic broad-spectrum coverage. Used for Complicated urinary tract infections (cUTI), Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), Complicated intra-abdominal infections (cIAI).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}